CRIS Current Research Information System

GRAMANTIERI, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.015
NA - Nord America 3.864
EU - Europa 2.761
AF - Africa 220
SA - Sud America 192
Continente sconosciuto - Info sul continente non disponibili 16
OC - Oceania 2
Totale 11.070
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.789
SG - Singapore 1.120
CN - Cina 1.053
VN - Vietnam 852
IT - Italia 838
GB - Regno Unito 417
DE - Germania 276
HK - Hong Kong 261
SE - Svezia 255
FR - Francia 191
NL - Olanda 165
IN - India 161
BR - Brasile 134
KR - Corea 128
RU - Federazione Russa 116
IE - Irlanda 98
JP - Giappone 96
BD - Bangladesh 91
CH - Svizzera 84
FI - Finlandia 77
ZA - Sudafrica 68
UA - Ucraina 61
CA - Canada 48
BG - Bulgaria 42
CI - Costa d'Avorio 41
ID - Indonesia 41
TG - Togo 40
TH - Thailandia 36
SC - Seychelles 32
EE - Estonia 28
PH - Filippine 28
JO - Giordania 23
EC - Ecuador 21
MX - Messico 21
PK - Pakistan 21
PL - Polonia 18
AT - Austria 16
IQ - Iraq 16
TW - Taiwan 16
EU - Europa 15
AR - Argentina 14
TR - Turchia 14
DZ - Algeria 13
BE - Belgio 12
HR - Croazia 10
MK - Macedonia 9
ES - Italia 8
LT - Lituania 8
UZ - Uzbekistan 8
MY - Malesia 7
PE - Perù 7
RO - Romania 7
NG - Nigeria 6
SA - Arabia Saudita 6
CL - Cile 5
CZ - Repubblica Ceca 5
GR - Grecia 5
IL - Israele 5
LB - Libano 5
AM - Armenia 4
EG - Egitto 4
MD - Moldavia 4
PY - Paraguay 4
AZ - Azerbaigian 3
CO - Colombia 3
IR - Iran 3
KZ - Kazakistan 3
MA - Marocco 3
NP - Nepal 3
TN - Tunisia 3
AE - Emirati Arabi Uniti 2
DK - Danimarca 2
ET - Etiopia 2
GH - Ghana 2
HU - Ungheria 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
SR - Suriname 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AU - Australia 1
BO - Bolivia 1
BY - Bielorussia 1
BZ - Belize 1
CR - Costa Rica 1
CU - Cuba 1
GE - Georgia 1
HN - Honduras 1
JM - Giamaica 1
KE - Kenya 1
KG - Kirghizistan 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LV - Lettonia 1
ML - Mali 1
MM - Myanmar 1
MR - Mauritania 1
NC - Nuova Caledonia 1
NO - Norvegia 1
Totale 11.064
Salva come PNG Salva come JPEG
Città #
Singapore 796
Ashburn 479
Southend 349
Fairfield 302
Hefei 272
San Jose 272
Bologna 265
Hong Kong 239
Chandler 214
Ho Chi Minh City 207
Hanoi 198
Santa Clara 165
Woodbridge 159
Houston 150
Boardman 132
Wilmington 131
Seattle 129
Beijing 119
Seoul 118
Council Bluffs 110
Dublin 98
Princeton 88
Dallas 83
Lauterbourg 80
Los Angeles 80
Ann Arbor 79
Cambridge 79
Bern 75
Tokyo 75
New York 66
Helsinki 61
Milan 53
Da Nang 50
Abidjan 41
Sofia 41
Lomé 40
Dong Ket 35
Jacksonville 34
Westminster 34
Amsterdam 33
Buffalo 33
Johannesburg 32
Nanjing 32
Padova 32
São Paulo 29
Redondo Beach 28
Florence 27
Haiphong 26
Chicago 25
Munich 25
Bengaluru 24
Berlin 24
Amman 23
Frankfurt am Main 22
Jakarta 22
Jinan 19
Rimini 19
Saint Petersburg 19
San Diego 19
Turin 18
Zhengzhou 18
Guangzhou 17
Hebei 17
Montreal 17
Orem 17
Rome 16
Shanghai 16
Bangkok 15
Düsseldorf 14
Imola 14
Nuremberg 13
Phoenix 13
Brooklyn 12
Hải Dương 12
Lahore 12
Nanchang 12
Toronto 12
Brussels 11
Des Moines 11
London 11
Shenzhen 11
Tianjin 11
Jiaxing 10
Parma 10
Pune 10
Quito 10
Shenyang 10
Vienna 10
Warsaw 10
Bremen 9
Changsha 9
Chennai 9
Denver 9
Forlì 9
Hangzhou 9
Medford 9
Mexico City 9
Naples 9
Norwalk 9
Tongling 9
Totale 7.000
Salva come PNG Salva come JPEG
Nome #
Circulating microRNAs, MIR-939, MIR-595, MIR-519d and MIR-494, identify cirrhotic patients with HCC 286
In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3–mediated apoptosis 271
MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma 242
Venom from Cuban Blue Scorpion has tumor activating effect in hepatocellular carcinoma 237
MiR-30e-3p influences tumor phenotype through MDM2/TP53 axis and predicts sorafenib resistance in hepatocellular carcinoma 236
Aflatoxin B1 DNA-Adducts in Hepatocellular Carcinoma from a Low Exposure Area 232
LncRNAs as novel players in hepatocellular carcinoma recurrence 224
MiR-22/GLUT1 Axis Induces Metabolic Reprogramming and Sorafenib Resistance in Hepatocellular Carcinoma 221
Early CTLA4 increase in CD45+ blood cells: an emerging biomarker of atezolizumab–bevacizumab resistance and worse survival in advanced hepatocarcinoma 221
Corrigendum: Vidatox 30 CH has tumor activating effect in hepatocellular carcinoma (Scientific Reports (2017) 7 (44685) DOI: 10.1038/srep44685) 215
Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin 214
Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. 203
Molecular and proteomic insight into Notch1 characterization in hepatocellular carcinoma 196
MicroRNA-Based Prophylaxis in a Mouse Model of Cirrhosis and Liver Cancer 191
Circulating CD8 lymphocytes predict response to atezolizumab–bevacizumab in hepatocellular carcinoma 189
Noncoding RNAs in Hepatocellular Carcinoma: Potential Applications in Combined Therapeutic Strategies and Promising Candidates of Treatment Response 187
MicroRNAs at the Crossroad between Immunoediting and Oncogenic Drivers in Hepatocellular Carcinoma 184
Different haemodynamic effects of a single dose of long-acting isosorbide-5-mononitrate in healthy subjects and patients with cirrhotic portal hypertension. 183
Direct antiviral treatments for hepatitis c virus have off-target effects of oncologic relevance in hepatocellular carcinoma 179
MiR-199-3p replacement affects E-cadherin expression through Notch1 targeting in hepatocellular carcinoma 178
p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma 178
MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. 170
Hepatic cancer stem cells: Molecular mechanisms, therapeutic implications, and circulating biomarkers 168
MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. 167
GADD45alpha expression in cirrhosis and hepatocellular carcinoma. Relationship with DNA-repair and proliferation. 167
TP53/MicroRNA interplay in hepatocellular carcinoma 166
Improving accuracy in the diagnosis of small HCC (< 20 mm) on cirrhosis by a combined CT-MRI Ultrasound navigation system. Preliminary report of a work in progress. 166
Tissue miRNA 483-3p expression predicts tumor recurrence after surgical resection in histologically advanced hepatocellular carcinomas 165
Oncogenic role of miR-483-3p at the IGF2/483 locus. 164
Animal Models of Hepatocellular Carcinoma: Current Applications in Clinical Research 161
F.N.27 NOTCH SIGNALLING CONTROLS PROLIFERATION AND SENESCENCE OF HUMAN HEPATOCELLULAR CARCINOMA 161
Targeting notch3 in hepatocellular carcinoma: Molecular mechanisms and therapeutic perspectives 159
MiR-122/Cyclin G1 Interaction Modulates p53 Activity and Affects Doxorubicin Sensitivity of Human Hepatocarcinoma Cells. 158
Notch Signaling and PD-1/PD-L1 Interaction in Hepatocellular Carcinoma: Potentialities of Combined Therapies 156
Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. 154
Frequent aberrant methylation of the CDH4 gene promoter in human colorectal and gastric cancer. 153
Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions 153
Multifaceted Aspects of Dysfunctional Myelopoiesis in Cancer and Therapeutic Perspectives with Focus on HCC 151
Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma (Targeted Oncology, (2020), 15, 6, (773-785), 10.1007/s11523-020-00757-3) 151
MicroRNAs in Animal Models of HCC 150
Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study 146
MicroRNA as predictive biomarkers of treatment response to tyrosine kinase inhibitors in hepatocellular carcinoma: how much is missing? 143
Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma. 140
MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. 139
Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma. 137
Brivanib in combination with Notch3 silencing shows potent activity in tumour models 136
Characterization of small nucleolar RNA retaining transcripts in human normal and cancer cells 132
T.N.28 P53 IS REGULATED BY NOTCH3 SIGNALLING VIA MDM2 IN HEPATOCELLULAR CARCINOMA 129
Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma 128
MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches 127
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 124
Efficacy of superselective TACE in treatment of HCC 120
MiR-122 targets serpinB3 and is involved in sorafenib resistance in hepatocellular carcinoma 119
c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma 115
MicroRNAs as Modulators of Tumor Metabolism, Microenvironment, and Immune Response in Hepatocellular Carcinoma 115
Low-Baseline PD1+ Granulocytes Predict Responses to Atezolizumab–Bevacizumab in Hepatocellular Carcinoma 114
Notch3 intracellular domain accumulates in HepG2 cell line. 110
Notch signaling regulation in HCC: From hepatitis virus to non‐coding rnas 110
Mir-30e-3p/CXCL3 axis is involved in sorafenib resistance of hepatocellular carcinoma through the modulation of the tumor immune microenvironment 106
Gut microbiome alterations and lenvatinib resistance in hepatocellular carcinoma: the role of Akkermansia muciniphila postbiotics in treatment enhancement 94
miR-30e-3p/CXCL3 axis predicts early tumor escape in sorafenib-treated hepatocellular carcinoma patients. 88
miRNA Signature of Hepatocellular Carcinoma Vascularization: How the Controls Can Influence the Signature 85
Emerging role of microRNAs in the treatment of hepatocellular carcinoma 83
Animal models of hepatocellular carcinoma prevention 78
null 77
miR-30e-3p/CXCL3 axis predicts early tumor escape in hepatocellular carcinoma patients undergoing sorafenib treatment 73
Towards precision medicine: a preliminary collection of patient-derived organoids for the screening of personalised therapies in hepatocellular carcinoma 72
Laboratory signs of acute or recent cytomegalovirus infection are common in cirrhosis of the liver 72
MiR-22-3p targets the G2/M checkpoint inhibitor Wee1 and represents a possible biomarker of TACE response in hepatocellular carcinoma 71
MiR-494 induces metabolic reprogramming through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma 70
Pathophysiology roles and translational opportunities of miRNAs in hepatocellular carcinoma 69
The tumour suppressor miR-22 induces metabolic reprogramming through GLUT1 targeting and represents a possible biomarker of Sorafenib response in Hepatocellular Carcinoma 66
MiR-22 downregulation activates HIF-1A pathway and induces tumour progression, metabolic reprogramming and sorafenib resistance in hepatocellular carcinoma 63
miR-30e-3p/CXCL3 axis predicts early tumor escape in sorafenib-treated HCC patients. 62
MiR-494 induces metabolic reprogramming through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma 59
CXCL3 is a target of miR-30e-3p and predicts tumor escape in sorafenib-treated HCC patients. 58
MiR-22 regulates HIF-1A pathway and tumor progression and represents a possible biomarker of sorafenib response in hepatocellular carcinoma 51
MiR-30e-3p plays a dual role in hepatocellular carcinoma and predicts tumour escape to sorafenib Treatment 49
Circulating microRNAs as biomarkers for stratifying different phases of liver cancer progression and response to therapy 44
Organic Electrochemical Transistors for Real-Time Detection of Immune System Early Activation during Atezolizumab-Bevacizumab Treatment in Hepatocellular Carcinoma 25
Circulating miR-22 Early Predicts TACE Non-Response and Targets WEE1 in Hepatocellular Carcinoma 18
Totale 11.324
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.180
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.180
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202198 0 0 0 0 0 0 0 0 0 0 0 98
2021/2022976 55 44 60 86 74 47 19 96 36 84 253 122
2022/20231.084 99 121 62 123 65 93 21 57 192 28 76 147
2023/2024411 32 70 19 37 55 79 13 20 19 30 13 24
2024/20251.731 87 222 141 116 214 55 121 45 44 181 133 372
2025/20265.172 421 427 400 322 455 327 526 243 1.094 359 300 298
Totale 11.324